Advanced CML: Therapeutic options for patients in accelerated and blast phases

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 6, Issue SUPPL. 2, 2008, Pages

  Shah, Neil P ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Accelerated phase; Blast crisis; Chronic myelogenous leukemia; Dasatinib; Imatinib; Nilotinib

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; NILOTINIB; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN TYROSINE KINASE INHIBITOR;

ADVANCED CANCER; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESEARCH; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOPENIA; CYTOTOXICITY; DISEASE DURATION; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; GENE MUTATION; HUMAN; LONG TERM CARE; RASH; RECOMMENDED DRUG DOSE; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

BLAST CRISIS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS;

EID: 45749097411     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417.
2. Gratwohl A, Hermans J, Niederwieser D, et al. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1993;12:509-516.
3. Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1996;17(Suppl 3):S5-6.
4. Brazma D, Grace C, Howard J, et al. Genomic profile of chronic myelogenous leukemia: imbalances associated with disease progression. Genes Chromosomes Cancer 2007;46:1039-1050.
5. Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 2006;103:2794-2799.
6. Griffin JD, Todd RF III, Ritz J, et al. Differentiation patterns in the blastic phase of chronic myeloid leukemia. Blood 1983;61:85-91.
7. Alimena G, De Cuia MR, Diverio D, et al. The karyotype of blastic crisis. Cancer Genet Cytogenet 1987;26:39-50.
8. Mitani K, Ogawa S, Tanaka T, et al. Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. Embo J 1994;13:504-510.
9. Fioretos T, Strombeck B, Sandberg T, et al. Isochromosome 17q in blast crisis of chronic myeloid leukemia and in other hematologic malignancies is the result of clustered breakpoints in 17p11 and is not associated with coding TP53 mutations. Blood 1999;94:225-232.
10. Collins SJ, Groudine MT. Chronic myelogenous leukemia: amplification of a rearranged c-abl oncogene in both chronic phase and blast crisis. Blood 1987;69:893-898.
11. Ahuja H, Bar-Eli M, Advani SH, et al. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc Natl Acad Sci U S A 1989;86:6783-6787.
12. Sill H, Goldman JM, Cross NC. Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood 1995;85:2013-2016.
13. Neviani P, Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005;8:355-368.
14. Neviani P, Santhanam R, Oaks JJ, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 2007;117:2408-2421.
15. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004;351:657-667.
16. Mullighan CG, Miller CB, Phillips LA, et al. IKZF1 (Ikaros) deletions are a hallmark of BCR-ABL1 positive acute lymphoblastic leukemia [abstract]. Blood 2007;110:Absttact 721.
17. Kantarjian HM, Talpaz M, Kontoyiannis D, et al. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor. J Clin Oncol 1992;10:398-405.
18. Enright H, McGlave P. Chronic myelogenous leukemia. In: Hoffman R, Benz EJ, Shattil SJ, et al., eds. Hematology: Basic Principles and Practice. 3rd ed. New York: Churchill Livingstone; 2000:1155-1171.
19. Griesshammer M, Arnold R, Bangerter M, et al. Chronic myeloid leukemia in accelerated phase: treatment results with conventional chemothetapy and allogeneic bone marrow transplantation in 96 patients. Eur J Haematol 1998;61:7-13.
20. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928-1937.
21. Silver RT, Talpaz M, Sawyers CL, et al. Four years follow-up of 1027 patients with late chronic phase, accelerated phase, or blast crisis chronic myeloid leukemia treated with imatinib in three large phase II trials [abstract]. Blood 2004;104:Abstract 23.
22. Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007;109:4143-4150.
23. Guilhot F, Apperley J, Kim DW, et al Efficacy of dasatinib in patients with accelerated phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-A (CA180-005) [abstract]. Blood 2007;110:Absttact 470.
24. le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated phase chronic myelogenous leukemia. Blood 2008;111:1834-1839.
25. le Coutre GP, Giles FJ, Apperley J, et al. Nilotinib is safe and effective in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or intolerance [abstract]. Blood 2007;110:Abstract 471.
26. Iacoboni SJ, Plunkett W, Kantarjian HM, et al. High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. J Clin Oncol 1986;4:1079-1088.
27. Sacchi S, Kantarjian HM, O'Brien S, et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 1999;86:2632-2641.
28. Derderian PM, Kantarjian HM, Talpaz M, et al. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am J Med 1993;94:69-74.
29. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530-3539.
30. Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007;109:3207-3213.
31. Gambacorti C, Cortes J, Kim DW, et al. Efficacy and safety of dasatinib in patients with chronic myeloid leukemia in blast phase whose disease is resistant or intolerant to imatinib: 2-year follow-up data from the START program [abstract]. Blood 2007;110:Abstract 472.
32. Shah NP, Skaggs BJ, Branford S, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007;117:2562-2569.
33. Soverini S, Martinelli G, Colarossi S, et al. Mutations at residues 315 and 317 in the ABL kinase domain are the main cause of resistance to dasatinib in Philadelphia-positive (Ph+) leukemia patients (pts) [abstract]. Blood 2006;108:Abstract 836.